Rezultati

eNauka >  Results >  Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial
Title: Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial
Authors : Holmes Frankie A; Moy Beverly; Delaloge Suzette; Chia Stephen KL; Ejlertsen Bent; Mansi Janine; Iwata Hiroji; Gnant Michael; Buyse Marc; Barrios Carlos H;
Silovski Tajana; Šeparović Robert; Bashford Anna; Zotano Guerrero Angel; Dendeluri Neelima; Patt Debra; Gokmen Erhan; Gore Ira; Smith II John W; Loibl Sibylle; Masuda Norikazu; Tomašević Zorica  ; Petrakova Katarina; DiPrimeo Daniel; Wong Alvin; Martin Miguel; Chan Arlene; ExteNET Study Group;
Issue Date: 2023
Publication: Eur J Cancer 184(May) 48-59
ISSN: 0959-8049 European Journal of Cancer / EJC Search Idenfier
Type: Article
Collation: vol. 184 str. 48-59
DOI: 10.1016/j.ejca.2023.02.002
WoS-ID: 000957574100001
Scopus-ID: 2-s2.0-85149461036
URI: https://enauka.gov.rs/handle/123456789/609947
https://zenodo.org/record/7808209
Project: pmid:36898233
issn:0959-8049
doi:10.1016/j.ejca.2023.02.002.
M-category: 
21aM21a

25
SCOPUSTM
21
WEB OF SCIENCETM
Alt metrika
Dimensions
Unpaywall

Rezultati na eNauka su zaštićeni autorskim pravima i sva prava su zadržana, osim ako nije drugačije naznačeno.